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Abstract  
Tropical climates provoke adaptations in skin pigmentation and in mechanisms controlling 
volume, salt-content and pressure of body fluids. For many whose distant ancestors moved to 
temperate climes, these adaptations proved harmful: pigmentation decreased by natural 
selection and susceptibility to hypertension emerged. Now an added risk is lung inflammation 
from coronavirus. Hypertension and coronavirus have in common angiotensin converting 
enzyme 2 (ACE2), which decreases blood pressure and mediates virus entry. In keeping with 
less detailed studies, a long-term case-report shows that decreased blood pressure induced by 
blocking a primary angiotensin receptor is supplemented, above critical blocker dosage, by a 
further temperature-dependent fall, likely mediated by ACE2 and a secondary angiotensin 
receptor. Temperature-dependence suggests a linkage with tropical heritage and an influence of 
blockers on the progress of coronavirus infections. Positive therapeutic results should result 
from negation of host pro-inflammatory effects mediated by the primary angiotensin receptor, 
and promotion of countervailing anti-inflammatory effects mediated by ACE2 through other 
receptors. Black vulnerability is likely based on physiological, not sociological, differences, 
which should guide treatment. 
Keywords: African ancestry, Angiotensin converting enzyme 2, Angiotensin receptors, 
Angiotensin receptor blockers, Environmental temperature, Hypertension, SARS-CoV-2.  
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Introduction  
Humans whose distant ancestors lived in tropical regions can differ biochemically and 
physiologically from those whose ancestors were in temperate regions. Increased sunlight and 
heat engender not only evolutionary differences in skin color (1), but also in cooling mechanisms 
that regulate the volume, salt-content and pressure of body fluids (2,3). This has influenced 
recommendations for treating hypertension, a disease to which those with dark skins are prone 
(4-6). To these major differences in responses to sunlight and heat, the coronavirus (SARS-CoV-
2) has added another – an increased mortality of those infected, often from inflammatory 
complications of lung disease.  
Thus, at an early stage of the present epidemic (April 12th 2020) the Chicago Department of 
Public Health reported that, while the percentage mortality in other groups was around 4%, for 
non-Latino blacks mortality was 22.7%. This extreme difference has been corroborated 
elsewhere (7, 8). Since those with pre-existing conditions are particularly vulnerable, the higher 
mortality could be explained in terms of general ill-health or sociological factors (9). However, 
given the degree of the disparity, differences in underlying physiology could play a major role.  
As a component of the renin-angiotensin system (RAS)(10), angiotensin II (Ang II) is 
fundamental to the regulation of blood pressure (BP; Fig. 1). The degrees to which 
countervailing Ang II receptors are activated could influence, not only BP, but also coronavirus 
therapy. SARS-CoV-2 enters cells by way of angiotensin converting enzyme 2 (ACE2)(11), 
which is generally protective for lung infections (10). Increased ACE2 gene transcription occurs 
during SARS-CoV-2 infection (12, 13). Thus, there is a relationship between coronavirus and a 
host’s physiological mechanisms for the control of the volume, salt-content and pressure of body 
fluids. Such mechanisms should be most severely tested in hot countries (e.g. sweating with loss 
of salt and water (14). Thus, it would be expected that, over evolutionary time, just as skin 
pigmentation became a fixed (non-inducible) adaptation in hot countries, so the fine-tuning of 
cooling mechanisms by natural selection could have resulted in stable, more extreme, adaptations 
than in temperate regions.  
However, being advantageous at one location at one point in time is not a guarantee of 
permanence. Adaptations may further evolve in diaspora. Skin pigmentation proved 
disadvantageous when populations moved to temperate climes and needed to synthesize vitamin 
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D. Pigmentation was decreased by natural selection, yet it could still be induced to return, albeit 
at lower levels (tanning), in response to radiation (1). Likewise, cooling mechanisms might prove 
counter-adaptive when challenged, either less severely by temperate climates, or more severely 
by pathogenic microorganisms. A combination of the two challenges could be fatal. 
 
Fig. 1. Regulation of BP and inflammation by countervailing receptors in the renin-
angiotensin system (RAS). The vasoconstrictory/pro-inflammatory pathway (thick grey arrows) 
is impeded at the level of the primary Ang II receptor by ARBs. Accumulated Ang II then drives 
the vasodilatory/anti-inflammatory pathway. Having entered by way of ACE2, SARS-CoV-2 
causes lung inflammation that can be opposed by the ARB-induced arrest of pro-inflammatory 
activity and stimulation of anti-inflammatory activity. The dashed line indicates an ARB-
dependent activation of the secondary Ang II receptor (25). 
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Knowledge that a RAS component, ACE2, was the SARS-CoV-2 receptor suggested that 
existing drugs employed to treat hypertension might be repurposed to treat coronavirus 
infections. Indeed, there are reports from China that angiotensin receptor blockers (ARBs) can 
mitigate the severity of SARS-CoV-2 infections (15). Their continued in-hospital use is 
associated with lower mortality risk compared with non-users (16). My earlier study of a 
temperature-dependent hypersensitivity of BP to an ARB (losartan), was interpreted in terms of a 
switch from primary to secondary countervailing receptors (17). I argue here that this mechanism 
supports the views, both that ARBs can mitigate the severity of acute inflammatory lung diseases 
whatever the etiology (10) and that, rather than “racism” (7), there is a fundamental 
physiological explanation for the high mortality of those whose distant ancestors lived in tropical 
regions.  
A recent stepwise regression study has identified both African-American origin and 
environmental temperature as significant variables, and has postulated a marginal vitamin D 
deficiency to explain the enhanced vulnerability of African-Americans to coronavirus (8). In 
contrast, my study, while also implicating temperature as a critical variable, has suggested 
differential evolved responses to heat-stress that might be influenced by ARBs. This has 
implications for control of SARS-CoV-2 infections in North America and for meeting the 
growing threat in Africa.  
 
Environmental temperature and response to ARBs 
 
Following short-term studies to determine efficacy and minimize adverse side-effects, losartan 
was introduced in the 1990s for the treatment of hypertension. A case report of its employment 
by an elderly white male as sole medication over a 12-year period (2003-2014), responded to 
calls for studies of possible long-term effects (17). There were also accounts, some anecdotal, of 
seasonal hyperresponsiveness to antihypertensive medications when environmental temperatures 
were high (17, 18). For the subject of the case report, doses had been adjusted daily with the goal 
of maintaining home-monitored BP readings (systolic/diastolic) close to 130/80 (mm Hg). Fig. 2 
shows that initially (2003-2010) this goal was consistently achieved with approximately 20 mg 
losartan daily and no relationship to temperature was evident. Then in late 2011 a need emerged 
to increase dosage close to 50 mg daily. This had been hinted at by small rises in December 2010 
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and early 2011. From this higher level, a marked and repeatable summer-time dip emerged 
(2012-2014). This was clearly seen in plots of dosage against temperature (Fig. 3). Indeed, when 
extrapolated, the plots indicated that no medication would be needed above 34oC – a temperature 
range more consistent with tropical locations than that of the subject (Canada). Since losartan 
was used world-wide, if not an individual idiosyncrasy, then this result had serious implications 
for the treatment of hypertension in equatorial regions (19, 20). 
 
 
Fig. 2. Environment temperature and monthly losartan requirement for a 12-year period 
(2003–2014). 2003, black triangles; 2004, dark yellow triangles; 2005, green circles; 2006, black 
squares; 2007, blue diamonds; 2008, orange squares; 2009, grey triangles; 2010, red 
diamonds; 2011, cyan circles; 2012, black circles; 2013, green diamonds; 2014, dark red 
circles. Data for 2012–2014 include standard errors. [From ref. (17); copyright DRF] 
 
Given that seasonal hyperresponsiveness to anti-hypertensive medications had been the 
subject – albeit not documented in individual detail – of previous reports, it was hoped that the 
possibility of individual idiosyncrasy would be discounted by further “crowd sourced” reports 
(21). Unlike previous reports that had not considered detailed mechanisms (e.g. (18) and (22)), it 
was proposed that the reported phenomena could be explained in terms of differential signaling 
by countervailing Ang II receptors – inhibition of a primary receptor that increased BP 
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(vasoconstriction) and activation, at a critical ARB concentration, of a secondary receptor that 
decreased BP (vasodilation)(17). The view that these observations were relevant to current 
considerations of a role of ARBs in the management of SARS-CoV-2 infections was encouraged 
by rapid developments in the biomedical literature, as will be set out here. It should be noted that 
there is generally little incentive for the pharmaceutical industry to carry out sustained long-term 
studies; hence, the call for “crowd sourcing” (21). Indeed, if discouraged by the absence of 
temperature effects during the first eight years (Figs. 2,3), the present study might well have been 
terminated at that stage. 
 
 
Fig. 3. Relationship between daily losartan requirements for the 2003-2014 period and 
corresponding maximum environmental temperatures. Least-squares regression fits to the 
points (third order polynomial) are shown as continuous lines for each year. Line coloring for 
different years follows that of Fig. 2. Consecutive r2 values for 2011–2014 were 0.22, 0.38, 0.34, 
and 0.45. [From ref. (17); copyright DRF] 
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With primary receptors for Ang II (AT1R subtype) blocked by losartan, there should be an 
increase in the concentration of Ang II that would then suffice to affect the losartan-insensitive, 
low abundance, secondary receptors (AT2R subtype). Reaction of excess Ang II with the 
secondary receptors would greatly amplify the fall in BP resulting from the losartan block of 
primary receptors (Fig. 1). An extensive literature based on both animal and human studies was 
cited as consistent with this (17).  
A similar scenario would have the excess of Ang II (an octapeptide) converted by ACE2 to 
Ang (1-7) (a septapeptide). This truncated Ang II fragment, by way of another receptor (MasR), 
also lowers BP (23,24). Either one, or both pathways acting collectively, should decrease BP 
(25). However, unexplained was the critical dependence on losartan dosage and the relationship 
to high environmental temperature (Figs. 2, 3). The latter raised the possibility that individuals 
retaining genetic linkages to ancestors who had adapted to tropical climes, might have particular 
responses to extrinsic agents, namely to drugs and to the SARS-CoV viruses that bind to ACE2 
(26) – but not to ACE1 (generally referred to as ACE, which has its own specific inhibitors 
referred to as ACEI). 
Of possible relevance to this hypothesis are reports that, as latitude decreases towards the 
equator, populations normally tend to have a lower BP (27), and that sub-Saharan Africans tend 
to be salt-sensitive regarding increasing BP (14). Furthermore, while experimental hypertension 
induced in rats by high salt diets does not respond to ARBs, that induced by the combination of 
salt and high environmental temperature is responsive (28). Although not concerned with the use 
of anti-hypertensive medications, a new study by Adam Li and his colleagues of black mortality 
in SARS-CoV-2 infections (8), suggests these results are relevant to humans.  
 
 
Role of ARBs in SARS-CoV-2 infection 
 
Given the dependence of SARS-CoV-2 on a host’s ACE2 receptor, an obvious issue is whether 
ARBs can affect, either negatively or positively, the progress of infection (29-31). Thus, it is 
proposed that the research community should “better outline the renin-angiotensin system and 
specifically ACE2 in the pathogenesis of COVID-19,” and that clinicians should accumulate 
more data “to determine if there is a link between the use of ACEIs, ARBs, or both, and COVID-
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19 mortality and morbidity” (32). In the absence of such information, various authorities have 
advised against stopping treatment, or switching to a BP treatment that does not involve the 
renin-angiotensin system (33,34). Furthermore, if administered to non-hypertensive patients, 
ARBs might provoke dangerous degrees of hypotension (19, 20).  
Current studies of SARS-CoV-2 are guided by the pioneering studies of SARS-CoV-1 
(usually referred to as SARS-CoV), which also enters cells by way of ACE2. SARS-CoV-1 
infectivity correlates with ACE2 expression (35). The Penninger laboratory showed that the lung 
inflammation responded to anti-hypertensive drugs, with ARBs being particularly effective 
(36,37). So, as recently recollected (26): “Thus, for SARS-CoV pathogenesis, ACE2 is not only 
the entry receptor of the virus but also protects from lung injury. We therefore … suggested that 
in contrast to most other coronaviruses, SARS-CoV became highly lethal because the virus 
deregulates a lung protective pathway.” 
 
SARS-CoV-2 deaths are mainly associated with respiratory failure association with virus-
induced inflammation (10,31,38). The ACE2 receptor (like the secondary Ang II receptor, AT2R) 
has an anti-inflammatory role and is incorporated with the virus on cell entry, so is lost from the 
cell surface. Sometimes such receptor down-regulation is a viral strategy to prevent 
superinfection by another, possibly competing, virus (39). However, this militates against any 
other roles a receptor may play. While there are also indications that SARS-CoV-2 can repress 
the gene encoding the ACE2 receptor, so that there is no receptor refurbishment (40), detailed 
transcriptional studies suggest that refurbishment is possible (12). Consistent with the human 
case history discussed here (17), RAS system-based anti-hypertensive agents (ARBs and ACEI) 
may stabilize or increase host refurbishment of ACE2 receptors, thus opposing their virus-
induced loss (41). However, a study of Butler and coworkers (12) concluded that with ACEI (but 
not with ARBs) there was “significantly increased risk of intubation and death.” 
 
Conclusions 
Investigations of this topic are in progress (32) and are likely to consider the well-reported age 
and gender differences. What can be added at this time is that the design and interpretation of 
clinical evaluations should factor in, not only variables such as tropical heritage (e.g. degree of 
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skin pigmentation), but also ambient temperatures, past and present ARB dosage, and the stage 
of the progression of a patient’s hypertension. In other words, ARBs, by decreasing the pro-
inflammatory effects of AT1R and hence supporting the anti-inflammatory effects of AT2R and 
ACE2 receptors, might be remedial under some circumstances, but not others. ARBs would 
operate, not by way of their ability to lower BP, but by way of their anti-inflammatory activities. 
Sensitivity to environmental temperature (8, 17) suggests, quite simply, that patients should be 
kept in warm environments. Indeed, the case doubling time is longer in tropical regions (42,43), 
indicating that those with unabridged RAS systems may be helped by higher temperatures. 
While much attention is rightly being given to possibilities of future effective anti-viral 
measures (vaccination and drugs affecting viral metabolism), highly experienced authorities are 
suggesting more emphasis on buttressing host defenses with what is now available. Thus, “an 
approach to treating patients with severe COVID-19 infection might be hiding in plain sight;” 
namely ARBs, perhaps employed in concert with another class of repurposable drug, the statins 
(44). If successful, this approach could allow herd immunity to develop without concomitant 
deaths and hence should decrease requirements for testing and contact-monitoring. 
 
REFERENCES AND NOTES 
 
1. N. G. Jablonski, Living Color. The Biological and Social Meaning of Skin Color 
(University of California Press, Berkeley, 2012). 
2. R. J. Roman, Pressure diuresis mechanism in the control of renal function and arterial 
pressure. Fed. Proc. 45, 2878-2884 (1986). 
3. C. G. Crandall, T. E. Wilson, Human cardiovascular responses to passive heat stress. 
Compr Physiol. 5, 17-43 (2015). 
4. S. G. Rostand, Ultraviolet light may contribute to geographic and racial blood pressure 
differences. Hypertension 30, 150-156 (1997). 
5. S. G. Rostand, L. A. McClure, S. T. Kent, S. E. Judd, O. M. Gutierrez, Associations of 
blood pressure, sunlight, and vitamin D in community-dwelling adults. J. Hypertens. 34, 
1704-1710 (2016). 
6. S. K. Williams, J. Ravenell, S. Seyedali, S. Nayef, G. Ogedegbe, Hypertension treatment 
in blacks: discussion of the U.S. clinical practice guidelines. Prog. Cardiovasc. Dis. 59, 
282-288 (2016). 
10 
 
 
 
7. I. X. Kendi, Stop blaming black people for dying of the coronavirus. New data from 29 
states confirm the extent of the racial disparities. The Atlantic, April 14 (2020). 
8. A.Y. Li, et al., Multivariate analysis of factors affecting COVID-19 case and death rate in 
U.S. counties: the significant effects of black race and temperature. medRxiv: 
https://doi.org/10.1101/2020.04.17.20069708 (2020). 
9. A. D. S. Burch, Why the virus is a civil rights issue: “The pain will not be shared equally” 
New York Times, April 21 (2020). 
10. H. Jia, Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung 
disease. Shock 46, 239-248 (2016). 
11. M. Hoffman et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is 
blocked by a clinically proven protease inhibitor. Cell 181, 271-280 (2020). 
12. D. J. Butler, et al., Host, viral, and environmental transcriptome profiles of the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). bioRxiv: 
https://doi.org/10.1101/2020.04.20.048066 (2020). 
13. M. Vaduganathan, et al., Renin–angiotensin–aldosterone system inhibitors in patients 
with Covid-19. New Eng. J. Med. doi: 10.1056/NEJMsr2005760 (2020). [Epub ahead of 
print] 
14. F. P. Cappuccio, M. A. Miller, Cardiovascular disease and hypertension in sub-Saharan 
Africa: burden, risk and interventions. Intern. Emerg. Med. 11, 299-305 (2016). 
15. Y. Liu, et al., Anti-hypertensive angiotensin II receptor blockers associated to mitigation 
of disease severity in elderly COVID-19 patients. medRxiv: 
https://doi.org/10.1101/2020.03.20.20039586 (2020).  
16. P. Zhang, et al., Association of inpatient use of angiotensin converting enzyme inhibitors 
and angiotensin II receptor blockers with mortality among patients with hypertension 
hospitalized with COVID-19. Circ. Res. doi: 10.1161/CIRCRESAHA.120.317134 (2020). 
[Epub ahead of print] 
17. D. R. Forsdyke, Summertime dosage-dependent hypersensitivity to an angiotensin II 
receptor blocker. BMC Res. Notes 8, 227 (2015). https://doi.org/10.1186/s13104-015-
1215-8 
18. K. Arakawa, A. Ibaraki, Y. Kawamoto, M. Tominaga, T.. Tsuchihashi. Antihypertensive 
drug reduction for treated hypertensive patients during the summer. Clin. Exp. 
Hypertens. 41, 389-393 (2019).  
19. E. Imai, K. Abe, Blood pressure drop in summer may cause acute kidney injury with 
irreversible reduction on glomerular filtration rate. Clin. Exp. Nephrol. 17, 1-2 (2013). 
11 
 
 
 
20. I. Sagy, A. Vodonos, V. Novack, B. Rogachev, Y. S. Haviv, I. Barski, The combined 
effect of high ambient temperature and antihypertensive treatment on renal function in 
hospitalized elderly patients. PLoS ONE 11, e0168504 (2016). 
21. D. R. Forsdyke, Doctor–scientist–patients who barketh not: the quantified self-movement 
and crowd-sourcing research. J. Eval. Clin. Pract. 21, 1021-1027 (2015). 
22. H. Zhao, S. Jivraj, A. Moody, ‘My blood pressure is low today, do you have the heating 
on?’ The association between indoor temperature and blood pressure. J. Hypertens. 37, 
504-512 (2019). 
23. C. M. Ferrario, et al., Effect of angiotensin-converting enzyme inhibition and angiotensin 
II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-
10 (2005).  
24. R. A. S. Santos, W. O. Sampaio, A. C. Alzamora, D. Motta‐Santos, N. Alenina, M. 
Bader, M. J. Campagnole‐Santos, The ACE2/angiotensin‐(1‐7)/MAS axis of the renin‐
angiotensin system: focus on angiotensin‐(1‐7). Physiol Rev. 98, 505-553 (2018). 
25. S. Bosnyak, R. E. Widdop, K. M. Denton, E. S. Jones, Differential mechanisms of Ang 
(1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int. J. 
Hypertens. 2012, 192567 (2012). 
26. H. Zhang, J. M. Penninger, Y. Li, N. Zhong, A. S. Slutsky, Angiotensin-converting 
enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential 
therapeutic target. Intens. Care Med. 46, 586-590 (2020). 
27. S. E. Cabrera, J. S. Mindell, M. Toledo, M. Alvo, C. J. Ferro, Associations of blood 
pressure with geographical latitude, solar radiation, and ambient temperature: results 
from the Chilean health survey, 2009-2010. Am. J. Epidemiol.183, 1071-1073 (2016). 
28. F. M. Agbaraolorunpo, A. K. Oloyo, C. N. Anigbogu, O. A  Sofola, Chronic exposure to 
high environmental temperature exacerbates sodium retention and worsens the severity 
of salt-induced hypertension in experimental rats via angiotensin receptor activation. J. 
Afr. Ass. Physiol. Sci. 7, 109-118 (2019). 
29. J. K. Aronson, R. E. Ferner, Drugs and the renin-angiotensin system in covid-19. Clinical 
effects are unpredictable, so treatment decisions must be tailored and pragmatic. Brit. 
Med. Assoc. J. 369, m1313 (2020). 
30. D. Focosi, M. Tuccori, M. Fabrizio, 2020 ACE inhibitors and AT1R blockers for COVID-
2019: friends or foes? www.preprints.org doi:10.20944/preprints202004.0151 
(2020).doi:10.2094 
12 
 
 
 
31. J. Guo, Z. Huang, L. Lin, J. Lv, Coronavirus disease 2019 and cardiovascular disease: a 
viewpoint on the potential influence of angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory 
syndrome coronavirus 2 infection. J. Am. Heart. Assoc. 9, e016219 (2020). 
32. A.B. Patel, A. Verma, COVID-19 and angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers. What is the evidence? J. Am. Med. Assoc. doi: 
10.1001/jama.2020.4812 (2020). [Epub ahead of print]   
33. R. Sommerstein, M. M. Kochen, F. H. Messerli, C. Gräni, Coronavirus disease 2019 
(COVID-19): Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 
have a biphasic effect? J. Am. Heart. Assoc. 9, e016509 (2020).  
34. K. L. Quinn, M. Fralick, J. S. Zipursky, N. M. Stall, (2020) Renin–angiotensin–
aldosterone system inhibitors and COVID-19. Can. Med. Assoc. J. doi: 
10.1503/cmaj.200619 (2020). [Epub ahead of print]   
35. H. Hofmann, S. Pöhlmann, Cellular entry of the SARS coronavirus. Trends Microbiol. 12, 
466-472 (2004). 
36. Y. Imai, et al., Angiotensin-converting enzyme 2 protects from severe acute lung failure. 
Nature 436, 112-116 (2005). 
37. K. Kuba, et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS 
coronavirus-induced lung injury. Nature Med. 11, 875-879 (2005).  
38. X. C. Li, J. Zhang, J. L. Zhuo, The vasoprotective axes of the renin-angiotensin system: 
Physiological relevance and therapeutic implications in cardiovascular, hypertensive and 
kidney diseases. Pharm. Res. 125, 21-38 (2017). 
39. D. R. Forsdyke, Evolutionary Bioinformatics (Springer, New York, ed. 3, 2016) pp. 185-
186. 
40. T. Fadason, et al., A transcription regulatory network within the ACE2 locus may 
promote a pro-viral environment for SARS-CoV-2 by modulating expression of host 
factors. bioRxiv: https://doi.org/10.1101/2020.04.14.042002 (2020). 
41. U. Bastolla, The differential expression of the ACE2 receptor across ages and gender 
explains the differential lethality of SARS-Cov-2 and suggests possible therapy. 
http://arXiv:2004.07224 (2020). 
42. J. Berumen, et al., Trends of SARS-Cov-2 infection in 67 countries: Role of climate 
zone, temperature, humidity and curve behavior of cumulative frequency on duplication 
time. medRxiv: https://doi.org/10.1101/2020.04.18.20070920 (2020).  
13 
 
 
 
43. A. Notari, Temperature dependence of COVID-19 transmission. arXiv:2003.12417 
(2020). 
44. D. S. Fedson, S. M. Opal, O. Rordam, Hiding in plain sight: an approach to treating 
patients with severe COVID-19 infection. mBio 11, e00398-20. 
https://doi.org/10.1128/mBio.00398-20 (2020). 
